期刊文献+

Calphostin C对乳腺癌细胞增殖的抑制作用及相关机制 被引量:3

Inhibition of Calphostin C on the proliferation of breast carcinoma cells and its mechanism
下载PDF
导出
摘要 目的研究Calphostin C对乳腺癌细胞MDA-MB-435S增殖的影响及初步机制。方法通过观察Calphostin C处理MDA-MB-435S细胞前后细胞的生长速度、倍增时间、克隆形成率和细胞周期分布等变化,探讨Calphostin C对MDA-MB-435S细胞增殖的影响;通过Western blotting、免疫细胞化学染色和RT-PCR等方法探讨Calphostin C影响MDA-MB-435S细胞增殖的初步机制。结果与MDA-MB-435S亲本细胞(对照组)相比,Calphostin C处理的MDA-MB-435S细胞(实验组)生长速度明显减慢,倍增时间明显延长(P<0.01),并且呈现浓度和时间依赖性;对照组和实验组细胞克隆形成率分别为(82.33±6.81)%和(22.00±1.73)%,差异有统计学意义(P<0.01);实验组细胞周期出现明显的G1期阻滞(P<0.01)。Western blotting和免疫细胞化学染色结果显示,与对照组细胞相比,实验组细胞中蛋白激酶Cα(protein kinase Cα,PKCα)表达没有明显变化,但活性状态(胞质转位至胞膜)的PKCα显著减少。West-ern blotting和RT-PCR结果显示,与对照组细胞相比,实验组细胞中p53、Cyclin A和Cyclin B表达没有明显变化,但p21表达上调,Cyclin E表达下调。结论Calphostin C可显著抑制乳腺癌细胞MDA-MB-435S的增殖,该作用可能与其抑制PKCα活性、上调p21表达和下调Cyclin E表达有关。 Objective To explore the effects of Calphostin C on the proliferation of breast carcinoma cells , 〈 (MDA-MB-435S) and its preliminary mechanism. Methods The effects of Calphostin C on the proliferation of MDA-MB-435S cells were studied by observing changes of the growth rate, doubling time, clone-forming efficiency, and distribution of cell cycle of MDA-MB-435S cells before and after Calphostin C treatment. Furthermore, the mechanism involved was analyzed by Western blotting, immunocytochemistry and RT-PCR assay. Results Compared with those of the parental MDA-MB-435S ceils (control group), the growth rate was suppressed markedly and the doubling time was prolonged significantly (P〈0.01) in the MDA-MB-435S cells treated with Calphostin C (experimental group), and the changes presented concentration- and time-dependence patterns. Furthermore, the clone-forming efficiency in control group and experimental group was (82.33 ± 6.81) % and (22.00 ± 1.73) %, respectively, with a significant difference (P〈 0.01). Moreover, for the experimental group cells, the cell cycle arrested in G1 phase (P〈0.01). The results from Western blotting and immunocytochemical staining indicated that compared with that of the parental MDA-MB-435S cells, the expression of protein kinase Ca (PKCa) did not change significantly, but PKCa in active status (transposition from cytoplasm to cytomembrane) was decreased dramatically in the MDA-MB-435S cells treated with Calphostin C. Western blotting and RT-PCR results showed that compared with that of the parental MDA-MB-435S cells, the expression of p53, Cyclin A and Cyelin B had no significant changes, while the expression of p21 was increased and the expression of Cyclin E was decreased in the MDA-MB- 435S cells treated with Calphostin C. Conclusion Calphostin C could suppress markedly the proliferation of MDA- MB-435S cells, which may be correlated to the abilities of inhibiting PKCa activity, up-regulating the expression of p21 and down-regulating the expression of Cyclin E.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2009年第5期582-586,共5页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 卫生部科研基金资助项目(No.WKJ2007-2-022) 河南省高校杰出科研人才创新工程资助项目(No.2007KYCX013)~~
关键词 钙磷酸蛋白C 蛋白激酶C 乳腺癌 增殖 Calphostin C protein kinase C breast carcinoma proliferation
  • 相关文献

参考文献10

  • 1ZHU Y,DONG Q,TAN BJ,et al.The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals[J].Cancer Res,2005,65(11):4520-4524.
  • 2CAMERON AJ,PROCYK KJ,LEITGES M,et al.PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival[J].Int J Cancer,2008,123(4):769-779.
  • 3TUTTLE KR,ANDERBERG RJ,COONEY SK,et al.Oxidative stress mediates protein kinase c activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet[J].Am J Nephrol,2008,29(3):171-180.
  • 4KOBAYASHI E,NAKANO H,MORIMOTO M,et al.Calphostin C (UCN-1028C),a novel microbial compound,is a highly potent and specific inhibitor of protein kinase C[J].Biochem Biophys Res Commun,1989,159(2):548-553.
  • 5PARKIN DM,BRAY F,FERLAY J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 6萨姆布鲁克 J,拉塞尔 DW.分子克隆实验指南[M].第3版.北京:科学出版社,2002:1713-1726.
  • 7MADDIKA S,ANDE SR,PANIGRAHI S,et al.Cell survival,cell death and cell cycle pathways are interconnected:implications for cancer therapy[J].Drug Resist Updat,2007,10(1-2):13-29.
  • 8KIM E,GIESE A,DEPPERT W.Wild-type p53 in cancer cells:when a guardian turns into a blackguard[J].Biochem Pharmacol,2009,77(1):11-20.
  • 9ABUKHDEIR AM,PARK BH.P21 and p27:roles in carcinogenesis and drug resistance[J].Expert Rev Mol Med,2008,10:e19.
  • 10HARPER JW,ADAMI GR,WEI N,et al.The p21Cdk-interacting protein Cipl is a protent inhibition of G1 cyclin-dependent kinases[J].Cell,1993,75(4):805-816.

同被引文献43

  • 1赵亚力,李琦,李向红,韩为东,郝好杰,司义玲,伍志强.EGFR基因在非小细胞肺癌、乳腺癌中突变的研究[J].遗传,2007,29(5):547-553. 被引量:4
  • 2Tsai RT, Tseng CK, Lee PJ, et al. Dynamic interactions of Ntrl-Ntr2 with Prp43 and with U5 govern the recruitment oi" Prp43 to mediate spliceosome disassembly [J]. Mol Cell Biol, 2007. 27 (23), 8027-8037.
  • 3Chen HH, Wang YC, Fann MJ. Identification and characterization of the CDKl2/cyclin L1 complex involved in alternative splicing regulation [J]. Mol Cell Biol, 2006. 26 (7): 2736-2745.
  • 4Tanaka, N, Aronova A. Schwer B. Ntrl activates the Prp43 helicase to trigger release of lariat-int ron from the spliceosome[J]. Genes Dev, 2007, 21 (18): 2312-2325.
  • 5Chen HH, Wong YH, Geneviere AM, et al. CDK13/ CDC21.5 interacts with L type eyclins and regulates alternative splicing [J]. lSioehem Biophys Res Commun, 2007, 35,t (3): 735-710.
  • 6Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins[J]. MolCell, 2003, 12 (1): 5-14.
  • 7Law WJ, Cann KJ, Hicks GG. TLS, EWS and TAF15: a model for transcriptional integration of gene expression [J]. Brief Funct Genomic Proteomic, 2006, 5 (1) : 8-14.
  • 8Li H, Katik |, Liu JP, Uses of telomerase peptides in anti- tumor immune therapy [J]. Methods Mol Biol, 2007, 405 (1) : 61-86.
  • 9Mustafa MM, Jamshed A, Khafaga Y, Mourad WA, A1-Mesfer S, Kofide A, et al. Adjuvant chemotherapy with vincristine, doxoru- bicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma [ J ]. J Pediatr Hematol Oncol, 1999,21 (5) :364-369.
  • 10Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Ca- ter J, et al. Postenucleation adjuvant therapy in high-risk retino- blastoma [ J ]. Arch Ophthalmol, 2002,120 ( 7 ) : 923 -931.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部